Latest news with #mid2026
The Verge
2 days ago
- Business
- The Verge
Warner Bros. Discovery will be Warner Bros. and Discovery after they break up
This time next year, the corporate entity known as Warner Bros. Discovery will be no more, and the two companies it's splitting into have some very inspired names. Today, Warner Bros. Discovery announced that 'Warner Bros.' and 'Discovery Global' are the names of the two new businesses that will exist after it completes its restructuring plan sometime in mid-2026. Warner Bros. will oversee Warner Bros. Television, Warner Bros. Motion Picture Group, DC Studios, HBO, HBO Max, and Warner Bros. Gaming Studios. And Discovery Global will be responsible for CNN, TNT's sports offerings in the US, Discovery, Discovery Plus, and Bleacher Report. WBD president and CEO David Zaslav will continue to lead the executive team at Warner Bros, while WBD's current chief financial officer Gunnar Wiedenfels will act as president and CEO for Discovery Global. In a statement about his new-ish role, Zaslav said that the corporate uncoupling will help put Warner Bros. into 'a strong position to launch and continue to meaningfully grow a company worthy of our storied past.' Wiedenfels echoed Zaslav's sentiment and insisted that Discovery Global's leadership team will 'ensure strong operational execution to drive strategic investments and deliver compelling content to global audiences.'WBD says that the new names are meant to honor 'the legacy of more than a century of industry-defining storytelling. But, everything about the company's restructuring reads very transparently as a move to deal with its massive debt problem. Technically speaking, Discovery Global's debt would no longer be attached directly to Warner Bros., which could help boost the company's flagging stock price. It's not exactly clear how Discovery Global plans to get itself back in the black, but the company is now looking for a new chief communications and public affairs officer who will probably be tasked with putting a positive spin on this whole situation. Posts from this author will be added to your daily email digest and your homepage feed. See All by Charles Pulliam-Moore Posts from this topic will be added to your daily email digest and your homepage feed. See All Business Posts from this topic will be added to your daily email digest and your homepage feed. See All Entertainment Posts from this topic will be added to your daily email digest and your homepage feed. See All Film Posts from this topic will be added to your daily email digest and your homepage feed. See All HBO Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Streaming Posts from this topic will be added to your daily email digest and your homepage feed. See All TV Shows
The Standard
26-06-2025
- Business
- The Standard
US dollar drops to lowest since 2021 against euro, sterling
Strategists at Morgan Stanley forecast the Dollar Index to drop to a level last seen during the COVID-19 pandemic by mid-2026. Photo by REUTERS
Yahoo
16-05-2025
- Business
- Yahoo
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ...
Cash and Cash Equivalents: $102.3 million at the end of Q1 2025. Net Cash Used in Operating Activities: $29.3 million for Q1 2025. Collaboration Revenue: $2.8 million for Q1 2025, down from $9.2 million in Q1 2024. Research and Development Expenses: $18.3 million for Q1 2025, compared to $18.7 million in Q1 2024. General and Administrative Expenses: $8.9 million for Q1 2025, down from $11.6 million in Q1 2024. Net Loss: $24.1 million for Q1 2025, compared to $19.3 million in Q1 2024. Warning! GuruFocus has detected 5 Warning Signs with MRSN. Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Mersana Therapeutics Inc (NASDAQ:MRSN) has implemented a strategic restructuring plan to extend its cash runway into mid-2026, allowing for continued development of its key product, Emi-Le. The company reported promising clinical data for Emi-Le, particularly in patients with B7-H4 high tumors, showing an objective response rate (ORR) of 29% and a median progression-free survival (PFS) of 16 weeks. Enrollment in the expansion cohort for Emi-Le has progressed rapidly, indicating strong interest and potential for further clinical success. Mersana Therapeutics Inc (NASDAQ:MRSN) has adopted new proteinuria management guidelines, which are expected to improve treatment tolerability and maintain dose intensity. The company has a solid financial position with $102.3 million in cash and cash equivalents, supporting its operations into mid-2026 without relying on future milestone payments or collaborations. Mersana Therapeutics Inc (NASDAQ:MRSN) has reduced its workforce by about 55% and eliminated internal pipeline development efforts, which may impact future innovation and development capabilities. The company's collaboration revenue decreased significantly from $9.2 million in Q1 2024 to $2.8 million in Q1 2025, reflecting reduced revenue from partnerships with J&J and Merck KGaA. Despite restructuring efforts, Mersana reported a net loss of $24.1 million for Q1 2025, an increase from the $19.3 million net loss in the same period of 2024. The focus on breast cancer in clinical development may limit the exploration of Emi-Le's potential in other tumor types, as expansion efforts in ovarian and endometrial cancers have been deprioritized. The company faces challenges in managing proteinuria, a side effect of Emi-Le, which requires careful mitigation strategies to avoid treatment delays and maintain efficacy. Q: Can you expand on the high dose, especially regarding safety and the updated protocol? Will this be included in the ASCO update? A: Brian Deschuytner, CFO and COO, explained that the data shared at ASCO will be based on escalation and backfill only, not expansion. The 44.5 mg/m dose is distinct and higher than the 67.4 mg/m dose, ensuring meaningful exposure. The 44.5 mg/m dose showed effectiveness in tumor reduction, but proteinuria management is crucial to maintain treatment without interruptions. Q: How might the ASCENT 3 and ASCENT 4 studies impact your clinical development plans in the post topo setting? A: Brian Deschuytner noted that the earlier use of topo-1 ADCs could expand the post topo-1 patient pool, where Mersana's Emi-Le has shown activity. This development is positive for patients and the opportunity size Mersana is pursuing. Q: Could you comment on the types of patients who showed responses at the intermediate dose? Also, how effective have the proteinuria management strategies been? A: Martin Huber, CEO, stated that the two additional responses were in ACC 1 patients. The proteinuria management strategies are not expected to eliminate proteinuria but aim to manage its consequences. The company is confident in these efforts and will share more details in the second half of the year. Q: Are there additional dosing regimens being evaluated beyond the current ones in expansion? What can we expect from the upcoming ASCO presentation? A: Brian Deschuytner confirmed that the current two doses are the focus for expansion, with no plans for additional regimens. The ASCO presentation will focus on backfill and escalation data, not expansion data. Q: Could you provide more color on a potential pivotal study and the cutoff for B7-H4 expression? A: Martin Huber discussed the benefits of a randomized trial over a single-arm trial, including global filing opportunities and avoiding confirmatory trials. The B7-H4 expression cutoff is being refined in expansion, but 40-50% of patients are expected to be positive. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
